LLS-funded researcher spotlights
The Leukemia & Lymphoma Society funds research across the continuum, from basic research through clinical trials, from bench to bedside. To date, we have invested more than $1 billion in research to advance therapies and save lives. LLS research grants have funded many of today's most promising advances, including targeted therapies and immunotherapies and some of the therapies first approved for blood cancer patients are now helping patients with other types of cancers and other serious diseases. Thanks to research and access to better treatments, survival rates for many blood cancer patients have doubled, tripled and even quadrupled since 1960.
hear from some of the world's most renowned blood cancer researchers about how LLS support helps makes it happen.
LLS funds research to advance more breakthrough therapies for blood cancer patients.
$15 M (5%)
$6.5 M (2%)
|Hodgkin Lymphoma |
$6.3 M (2%)
$15 M (5%)
$69 M (25%)
$16.7 M (6%)
|CLL / SLL
$20.9 M (7%)
$22.5 M (8%)
$40.1 M (14%)
$37.1 M (13%)
|MDS / MPNs |
$37.3 M (13%)
First chemo-therapy agents for lymphoma and leukemia patients, including children.
First combination chemotherapy developed for childhood leukemia.
First successful bone marrow transplants performed.
Cancer-causing oncogenes and tumor suppressor genes discovered.
Antibody-based therapies such as Rituxan.
Targeted therapies such as Gleevec.
Genomic medicine and precision medicine; adoptive immunotherapy.
Personalized medicine cures and prevention.